<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01034514</url>
  </required_header>
  <id_info>
    <org_study_id>LUN0034</org_study_id>
    <secondary_id>SU-04232009-2382</secondary_id>
    <nct_id>NCT01034514</nct_id>
  </id_info>
  <brief_title>4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy</brief_title>
  <official_title>4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Billy W. Loo Jr.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop and investigate a novel radiotherapy technique for preserving lung function based
      on a map of lung function.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    business decision
  </why_stopped>
  <start_date type="Actual">December 2009</start_date>
  <completion_date type="Actual">June 24, 2014</completion_date>
  <primary_completion_date type="Actual">June 24, 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The overall correlation between the 4D-CT and the SPECT ventilation images.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference between the local ventilation at simulation and during the treatment. Dose-volume or functional dose-volume metrics. The regression coefficient between the regional ventilation and time. The mean dose to the high-functional lung region.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>4DCT arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients breathe in 99mTc-DTPA and then undergo ventilation scans using a SPECT scanner over 2 hours. Patients also receive 99mTc-MAA IV and then undergo perfusion scans using a SPECT scanner over 2 hours. Patients may also undergo a pre- and post-treatment Xe-CT ventilation scan over 15 minutes and a pre-treatment 4D-CT scan over 5-10 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Real-time Position Management system</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>4DCT arm</arm_group_label>
    <other_name>RPM System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Discovery ST multislice PET/CT scanner</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>4DCT arm</arm_group_label>
    <other_name>Positron Emission Tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Infinia Hawkeye SPECT/CT gamma camera</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>4DCT arm</arm_group_label>
    <other_name>Single-photon emission computed tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pinnacle3 treatment planning system</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>4DCT arm</arm_group_label>
    <other_name>Radiation Treatment Planning</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SKYLight nuclear camera</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>4DCT arm</arm_group_label>
    <other_name>Philips Medical Systems</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTPA</intervention_name>
    <description>1 mCi; inhalation</description>
    <arm_group_label>4DCT arm</arm_group_label>
    <other_name>DRAXIS Specialty Pharmaceuticals Inc.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TECHNETIUM TC 99M MAA</intervention_name>
    <description>3 mCi; iv</description>
    <arm_group_label>4DCT arm</arm_group_label>
    <other_name>DRAXIS Specialty Pharmaceuticals Inc.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible disease(s)/stage(s) AJCC Stage I, II, III or IV lung cancer of any histology
             to be treated using radiotherapy will be eligible for this study. Note that we will
             carefully consider the inclusion of cases with turbulent flow or greater flow
             velocities (Cabahug et al., 1996; Crawford et al., 1990) and COPD cases (Magnant et
             al., 2006) due to the impaction of aerosol particles in central airways.

          -  Allowable type and amount of prior therapy. Any types and amounts of prior therapy
             will be allowed for this study.

          -  Age restriction and/or gender/ethnic restrictions

          -  Patients must be greater than or equal to 18 years of age.

          -  There are no gender or ethnic restrictions.

          -  Life expectancy restrictions - None.

          -  ECOG or Karnofsky Performance Status

          -  Not employed. Note that patients will need to be sufficiently healthy to undergo
             audiovisual (AV) biofeedback to generate high quality 4D-CT images.

          -  Requirements for organ and marrow function None.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

        Children (less than 18 years of age), pregnant women, Stanford employees or students, or
        prisoners will be excluded from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Billy Loo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2009</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Billy W. Loo Jr.</investigator_full_name>
    <investigator_title>Associate Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Technetium Tc 99m Aggregated Albumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

